Home / Market News / $HRTX

$HRTX news and market catalysts

The 4 most recent market catalysts affecting $HRTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 1 high impact 0 bullish 3 bearish Pharmaceuticals
Nov 9, 2026 Corporate Catalyst Neutral Impact 75
Heron Therapeutics Reports Third Quarter 2026 Financial Results
Heron Therapeutics announced its Q3 2026 financial results, revealing a decrease in total net revenue compared to the same period last year. This revenue decline is a significant c…
Aug 11, 2026 Corporate Catalyst Bearish Impact 55
HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral
HC Wainwright & Co. analyst Brandon Folkes downgraded Heron Therapeutics (HRTX) from a 'Buy' to a 'Neutral' rating. This matters because analyst ratings can influence investor sent…
Aug 10, 2026 Corporate Catalyst Bearish Impact 75
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Heron Therapeutics (HRTX). The worse-than-expected Q2 financial results directly impact the company's valuation and in…
Aug 10, 2026 Corporate Catalyst Bearish Impact 95
Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate
Heron Therapeutics (HRTX) reported a Q2 EPS of $(0.03), missing the analyst consensus of $(0.01) by an 'Infinity percent' (indicating a larger loss than anticipated), and sales of …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.